# Fifth Circuit Blocks Mailed Abortion Pill, But Stay Puts Ruling on Hold  
**Published:** 2026-05-06T21:33:10.000Z  
**Source:** [Nebraska Attorney General](https://ago.nebraska.gov/us-fifth-circuit-court-appeals-panel-judges-blocks-access-through-mail-mifepristone-abortion-pill)  
**AI-generated:** yes (claude-haiku-4-5-20251001)  
**Canonical:** https://lincolne.news/article/fifth-circuit-blocks-mailed-abortion-pill-but-stay-puts-ruling-on-hold

The U.S. Court of Appeals for the Fifth Circuit issued a nationwide stay Friday that would block access to mifepristone, the chemical abortion pill, through mail and telehealth appointments, according to [Nebraska Attorney General Mike Hilgers](https://ago.nebraska.gov/us-fifth-circuit-court-appeals-panel-judges-blocks-access-through-mail-mifepristone-abortion-pill). The ruling, if it stands, would make it illegal for out-of-state doctors to prescribe and ship the medication to Nebraska patients.

The decision came in a lawsuit filed by Louisiana that challenged a 2023 Biden administration regulation removing the requirement for in-person dispensing of mifepristone. However, early on Monday, May 4, 2026, the Supreme Court issued an administrative stay of the Fifth Circuit's order until May 11, effectively restoring the status quo for at least a week.

Nebraska was among 21 states that filed an amicus brief in February 2026 supporting Louisiana's challenge. Hilgers argued that the 2023 rule illegally overrode state abortion regulations and encroached on Nebraska's sovereign authority to set abortion policy following the 2022 Supreme Court decision in _Dobbs v. Jackson Women's Health Organization_, which devolved to state governments the authority to regulate any aspect of abortion.

The two-drug combination of mifepristone and misoprostol accounted for more than 98% of medication abortions in the United States in 2020. More than 1 in 4 people in the U.S. who have an abortion do so using telemedicine. Without this method of care delivery, patients using mifepristone would be forced to travel, sometimes hundreds of miles, to a health center just to pick up a pill, a requirement that leading medical authorities agree has no safety benefit.

The case remains pending in lower courts, and the FDA's comprehensive review of mifepristone, which began in September 2025, continues in the background, though the agency has not committed to a timeline for completing its review. The results of that review could also influence the ongoing proceedings in this and other cases. The Supreme Court is expected to rule May 11 on whether to extend the stay while litigation proceeds.

## Sources

- [Nebraska Attorney General](https://ago.nebraska.gov/us-fifth-circuit-court-appeals-panel-judges-blocks-access-through-mail-mifepristone-abortion-pill)
- [ReedSmith analysis of Fifth Circuit stay and Supreme Court administrative stay](https://www.reedsmith.com/our-insights/blogs/health-industry-washington-watch/102mrno/fifth-circuit-stay-reinstates-nationwide-in-person-dispensing-requirement-for-mif/)
- [Guttmacher Institute report on Fifth Circuit mifepristone decision](https://www.guttmacher.org/news-release/2026/fifth-circuit-decision-directs-fda-restrict-mifepristone-access)

---

This article was generated by AI (claude-haiku-4-5-20251001) based on source material from Nebraska Attorney General, enriched with 3 web searches. The original source is available at https://ago.nebraska.gov/us-fifth-circuit-court-appeals-panel-judges-blocks-access-through-mail-mifepristone-abortion-pill.